Axillary Surgery for Early-Stage, Node-Positive Mastectomy Patients and the Use of Postmastectomy Chest Wall Radiation Therapy

  • Sara Gaines
  • Nicholas Suss
  • Ermilo Barrera
  • Catherine Pesce
  • Kristine Kuchta
  • D. J. Winchester
  • Katharine Yao
Breast Oncology

Abstract

Background

We examined axillary surgery in mastectomy patients with tumor-positive nodes and how the type of axillary surgery impacted use of postmastectomy chest wall radiation therapy (PMRT).

Methods

Using the National Cancer Data Base, we selected patients with AJCC cT1/T2c N0 breast cancer with one to three tumor-positive lymph nodes treated between 2013 and 2014. Type of axillary surgery was analyzed using the FORDS scope of regional lymph node surgery variable. Multivariable logistic regression modeling was used to identify independent predictors associated with SNB alone and the use of PMRT.

Results

Of 8089 patients, 2482 (30.7%) underwent SNB alone, 1339 (16.6%) underwent axillary dissection (ALND) alone, and 4268 (52.7%) underwent SNB followed by ALND. Fifty-seven percent of patients with micrometastases underwent SNB alone compared with 22.6% of patients with macrometastases. Independent predictors of SNB alone for patients with micrometastases were African American race, number of nodes positive, and PMRT. For patients with macrometastases, age, facility type and location, and PMRT were independent predictors for SNB alone. Of 2449 patients who underwent SNB alone, 1538 (62.8%) had no PMRT, 261 (10.7%) had PMRT alone, and 650 (26.5%) had PMRT with regional nodal irradiation. Patients undergoing SNB alone were 1.70 times [96% confidence interval (CI) 1.45–2.00] more likely to undergo PMRT than upfront ALND and 1.51 times (96% CI 1.34–1.71) more likely than SNB followed by ALND.

Conclusions

Surgeons are omitting completion ALND in a third of early-stage, node-positive mastectomy patients. SNB alone patients are more likely to undergo PMRT than patients undergoing ALND.

Notes

Acknowledgement

None to report.

Disclosure

The authors declare no conflicts of interest.

References

  1. 1.
    Gradishar WJ, Anderson BO. NCCN Guidelines Version 2.2017 Invasive Breast Cancer. National Comprehensive Cancer Network.2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  2. 2.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, et al. Axillary vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6)569–75.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Galimberti V, Cole BF, Zurrida S, Luini A, Veronesi P, Baratella P, Chifu, C, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, Moral A, et al. Complete Axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(1):120–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Runovszky G, Kovács E, Gyorffy B, et al. Eight-year follow up result of the OTOASOR trial: The optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672–9.CrossRefPubMedGoogle Scholar
  7. 7.
    National Comprehensive Cancer Guidelines Version 3.2017. https://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
  8. 8.
    Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ. Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the number of axillary node removed for patients with early-stage breast cancer. J Am Coll Surg. 2015;221(1):71–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Woznick A, Franco M, Bendick P, Benitez PR. Sentinel lymph node dissection for breast cancer: how many nodes are enough and which technique is optimal. Ann J Surg. 2006;191(3):330–3.CrossRefGoogle Scholar
  10. 10.
    Olaya W, Wong J, Morgan J, Kazanjian K, Lum S. When is a lymph node dissection a lymph node dissection? The number of lymph nodes resected in sentinel and axillary lymph node dissections. Ann Surg Oncol. 2013;20(2):627–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol. 2009;27(25):4177–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Lerro CC, Robbins AS, Phillip JL, Stewart AK. Comparison of cases captured in the National Cancer Database with those in population-based central cancer registries. Ann Surg Oncol. 2013;20(6):1759–65.CrossRefPubMedGoogle Scholar
  13. 13.
    Facility Oncology Registry Data Standards (FORDS), Commission on Cancer of the American College of Surgeons, Revised 2016.Google Scholar
  14. 14.
    U.S. Census. About race. Washington (DC): US Census Bureau; 2010. http://www.census.gov/topics/population/race/about.html.
  15. 15.
    National Cancer Data Base—Participate User File. 2015 http://ncdbpuf.facs.org.
  16. 16.
    Deyo RA, Cherkin DC, Cio MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMedGoogle Scholar
  17. 17.
    American College of Surgeons. CoC accreditation categories. 2016. https://www.facs.org/quality%20programs/cancer/coc/apply.
  18. 18.
    US Census. Statistical Groupings of States and Counties. Washington (DC): US Census Bureau; 2010. https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf.
  19. 19.
    AJCC Cancer Staging Manual. 7th edn. Chicago, IL: Springer; 2010.Google Scholar
  20. 20.
    Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, Giuliano A, Haffty BG. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014;32(32):3600–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fu Y, Chung D, Cao MA, Apple S, Chang H. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? Ann Surg Oncol. 2014;21(13):4109–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, et al. Outcomes of post mastectomy radiation therapy in patients receiving axillary lymph node dissection after positive sentinel lymph node biopsy. Int J Rad Oncol. 2016;96(3):637–44.Google Scholar
  23. 23.
    Schrenk P, Hatzl-Griesenhofer, Shamiyeh A, Waynad W. Follow-up of sentinel node-negative breast cancer patients without axillary node dissection. J Surg Oncol. 2001;77:165–170.CrossRefPubMedGoogle Scholar
  24. 24.
    Schlag PM, Bembenek A. Specification of potential indications and contraindications of sentinel lymph node biopsy in breast cancer. Recent Results Cancer Res. 2000;157:228–236.CrossRefPubMedGoogle Scholar
  25. 25.
    Sener SF, Winchester DJ, Brinkmann E, Winchester DP, Alwawi E, Nickolov A, Perlman RM, et al. Failure of sentinel lymph node mapping in patients with breast cancer. J Am Coll Surg. 2004;198(5):732–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Barco I, Chabrera C, García-Fernández A, Fraile M, González S, Canales L, Lain JM, et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer. Clin Transl Oncol. 2017;19(6):704–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Krag DN, Anderson SJ, Julian TB, Brown Am, Harlow AP, Ashikaga T, Weaver DL, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Chagpar AB, Martin RC, Scoggins CR, Carlson DJ, Laidley Al, El-Eid SE, McGlothin TQ, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005;138(1):56–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple-negative breast cancer. BMC Cancer. 2014;14:62.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15(4):248–54.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, et al. Impact of the American College of Surgeons Oncology Group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013;216(1)105–13.CrossRefPubMedGoogle Scholar
  33. 33.
    de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17(1):379.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, et al. Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. Ann Surg Oncol. 2017;24(3)652–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762–70.CrossRefPubMedGoogle Scholar
  36. 36.
    van Roozendaal LM, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Boersma LJ, Linn SC, et al. Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized, controlled multicenter trial (BOOG 2013-08). BMC Cancer. 2017;17(1):459.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Sara Gaines
    • 1
  • Nicholas Suss
    • 2
  • Ermilo Barrera
    • 2
  • Catherine Pesce
    • 2
  • Kristine Kuchta
    • 3
  • D. J. Winchester
    • 2
  • Katharine Yao
    • 2
    • 4
    • 5
  1. 1.Department of SurgeryUniversity of ChicagoChicagoUSA
  2. 2.Department of SurgeryNorthShore University HealthSystemEvanstonUSA
  3. 3.Biostatistical CoreNorthShore University HealthSystem Research InstituteEvanstonUSA
  4. 4.Division of Surgical Oncology, Department of SurgeryNorthShore University HealthSystemEvanstonUSA
  5. 5.Pritzker School of MedicineUniversity of ChicagoChicagoUSA

Personalised recommendations